Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 362

1.

Nausea and vomiting of pregnancy: A study with pregnancy-unique quantification of emesis questionnaire.

Ellilä P, Laitinen L, Nurmi M, Rautava P, Koivisto M, Polo-Kantola P.

Eur J Obstet Gynecol Reprod Biol. 2018 Nov;230:60-67. doi: 10.1016/j.ejogrb.2018.09.031. Epub 2018 Sep 14.

PMID:
30243227
2.

Quantitative Prediction of CYP3A4 Induction: Impact of Measured, Free, and Intracellular Perpetrator Concentrations from Human Hepatocyte Induction Studies on Drug-Drug Interaction Predictions.

Sun Y, Chothe PP, Sager JE, Tsao H, Moore A, Laitinen L, Hariparsad N.

Drug Metab Dispos. 2017 Jun;45(6):692-705. doi: 10.1124/dmd.117.075481. Epub 2017 Mar 23.

PMID:
28336578
3.

VX-509 (Decernotinib)-Mediated CYP3A Time-Dependent Inhibition: An Aldehyde Oxidase Metabolite as a Perpetrator of Drug-Drug Interactions.

Zetterberg C, Maltais F, Laitinen L, Liao S, Tsao H, Chakilam A, Hariparsad N.

Drug Metab Dispos. 2016 Aug;44(8):1286-95. doi: 10.1124/dmd.116.071100. Epub 2016 Jun 13.

PMID:
27298338
4.

[Heterotopic pregnancy during the second trimester is a severe complication of pregnancy].

Färkkilä A, Laitinen L.

Duodecim. 2016;132(8):730-3. Finnish.

PMID:
27244932
5.

Prolonged low-molecular-weight heparin use during pregnancy and subsequent bone mineral density.

Galambosi P, Hiilesmaa V, Ulander VM, Laitinen L, Tiitinen A, Kaaja R.

Thromb Res. 2016 Jul;143:122-6. doi: 10.1016/j.thromres.2016.05.016. Epub 2016 May 19.

PMID:
27236710
6.

Discovery of VX-509 (Decernotinib): A Potent and Selective Janus Kinase 3 Inhibitor for the Treatment of Autoimmune Diseases.

Farmer LJ, Ledeboer MW, Hoock T, Arnost MJ, Bethiel RS, Bennani YL, Black JJ, Brummel CL, Chakilam A, Dorsch WA, Fan B, Cochran JE, Halas S, Harrington EM, Hogan JK, Howe D, Huang H, Jacobs DH, Laitinen LM, Liao S, Mahajan S, Marone V, Martinez-Botella G, McCarthy P, Messersmith D, Namchuk M, Oh L, Penney MS, Pierce AC, Raybuck SA, Rugg A, Salituro FG, Saxena K, Shannon D, Shlyakter D, Swenson L, Tian SK, Town C, Wang J, Wang T, Wannamaker MW, Winquist RJ, Zuccola HJ.

J Med Chem. 2015 Sep 24;58(18):7195-216. doi: 10.1021/acs.jmedchem.5b00301. Epub 2015 Sep 10.

PMID:
26230873
7.

Effect of smoking on use of antibacterials: a 9-year follow-up study of 24 000 working-aged Finns.

Koskenvuo K, Huunan-Seppälä A, Keistinen T, Autti-Rämö I, Laitinen LA, Koskenvuo M.

Tob Control. 2013 Jul;22(4):280-6. doi: 10.1136/tobaccocontrol-2011-050128. Epub 2012 Jan 17.

PMID:
22253002
8.

Low plasma antibodies specific for phosphatidylethanol in alcohol abusers and patients with alcoholic pancreatitis.

Nissinen AE, Laitinen LM, Kakko S, Helander A, Savolainen MJ, Hörkkö S.

Addict Biol. 2012 Nov;17(6):1057-67. doi: 10.1111/j.1369-1600.2010.00279.x. Epub 2011 Feb 11.

PMID:
21309928
9.

Production and purification of lentiviral vectors generated in 293T suspension cells with baculoviral vectors.

Lesch HP, Laitinen A, Peixoto C, Vicente T, Makkonen KE, Laitinen L, Pikkarainen JT, Samaranayake H, Alves PM, Carrondo MJ, Ylä-Herttuala S, Airenne KJ.

Gene Ther. 2011 Jun;18(6):531-8. doi: 10.1038/gt.2010.162. Epub 2011 Jan 20.

PMID:
21248790
10.

Attenuated expression of tenascin-C in ovalbumin-challenged STAT4-/- mice.

Meuronen A, Karisola P, Leino M, Savinko T, Sirola K, Majuri ML, Piirilä P, Virtanen I, Mäkelä M, Laitinen A, Laitinen LA, Alenius H.

Respir Res. 2011 Jan 4;12:2. doi: 10.1186/1465-9921-12-2.

11.

Smoking strongly predicts disability retirement due to COPD: the Finnish Twin Cohort Study.

Koskenvuo K, Broms U, Korhonen T, Laitinen LA, Huunan-Seppälä A, Keistinen T, Autti-Rämö I, Kaprio J, Koskenvuo M.

Eur Respir J. 2011 Jan;37(1):26-31. doi: 10.1183/09031936.00008910. Epub 2010 Jun 1.

12.

In vitro and in vivo isotope effects with hepatitis C protease inhibitors: enhanced plasma exposure of deuterated telaprevir versus telaprevir in rats.

Maltais F, Jung YC, Chen M, Tanoury J, Perni RB, Mani N, Laitinen L, Huang H, Liao S, Gao H, Tsao H, Block E, Ma C, Shawgo RS, Town C, Brummel CL, Howe D, Pazhanisamy S, Raybuck S, Namchuk M, Bennani YL.

J Med Chem. 2009 Dec 24;52(24):7993-8001. doi: 10.1021/jm901023f.

PMID:
19894743
13.

Biological and genetic interaction between tenascin C and neuropeptide S receptor 1 in allergic diseases.

Orsmark-Pietras C, Melén E, Vendelin J, Bruce S, Laitinen A, Laitinen LA, Lauener R, Riedler J, von Mutius E, Doekes G, Wickman M, van Hage M, Pershagen G, Scheynius A, Nyberg F, Kere J; PARSIFAL Genetics Study Group.

Hum Mol Genet. 2008 Jun 1;17(11):1673-82. doi: 10.1093/hmg/ddn058. Epub 2008 Feb 27.

14.

Evaluation of mesoporous TCPSi, MCM-41, SBA-15, and TUD-1 materials as API carriers for oral drug delivery.

Heikkilä T, Salonen J, Tuura J, Kumar N, Salmi T, Murzin DY, Hamdy MS, Mul G, Laitinen L, Kaukonen AM, Hirvonen J, Lehto VP.

Drug Deliv. 2007 Aug;14(6):337-47.

PMID:
17701523
15.

Surface chemistry and pore size affect carrier properties of mesoporous silicon microparticles.

Limnell T, Riikonen J, Salonen J, Kaukonen AM, Laitinen L, Hirvonen J, Lehto VP.

Int J Pharm. 2007 Oct 1;343(1-2):141-7. Epub 2007 May 16.

PMID:
17600644
16.

Effect of cell differentiation and passage number on the expression of efflux proteins in wild type and vinblastine-induced Caco-2 cell lines.

Siissalo S, Laitinen L, Koljonen M, Vellonen KS, Kortejärvi H, Urtti A, Hirvonen J, Kaukonen AM.

Eur J Pharm Biopharm. 2007 Sep;67(2):548-54. Epub 2007 Mar 28.

PMID:
17475454
17.

Chronic bronchitis and chronic obstructive pulmonary disease. The Finnish Action Programme, interim report.

Pietinalho A, Kinnula VL, Sovijärvi AR, Vilkman S, Säynäjäkangas O, Liippo K, Kontula E, Laitinen LA.

Respir Med. 2007 Jul;101(7):1419-25. Epub 2007 Mar 13.

18.

Enhanced in vitro permeation of furosemide loaded into thermally carbonized mesoporous silicon (TCPSi) microparticles.

Kaukonen AM, Laitinen L, Salonen J, Tuura J, Heikkilä T, Limnell T, Hirvonen J, Lehto VP.

Eur J Pharm Biopharm. 2007 Jun;66(3):348-56. Epub 2006 Dec 1.

PMID:
17240128
19.

In-vitro mutagenic potential and effect on permeability of co-administered drugs across Caco-2 cell monolayers of Rubus idaeus and its fortified fractions.

Kreander K, Galkin A, Vuorela S, Tammela P, Laitinen L, Heinonen M, Vuorela P.

J Pharm Pharmacol. 2006 Nov;58(11):1545-52.

PMID:
17132218
20.

Anthranoid laxatives influence the absorption of poorly permeable drugs in human intestinal cell culture model (Caco-2).

Laitinen L, Takala E, Vuorela H, Vuorela P, Kaukonen AM, Marvola M.

Eur J Pharm Biopharm. 2007 Apr;66(1):135-45. Epub 2006 Sep 28.

PMID:
17098405
21.

Mesoporous silica material TUD-1 as a drug delivery system.

Heikkilä T, Salonen J, Tuura J, Hamdy MS, Mul G, Kumar N, Salmi T, Murzin DY, Laitinen L, Kaukonen AM, Hirvonen J, Lehto VP.

Int J Pharm. 2007 Feb 22;331(1):133-8. Epub 2006 Sep 19.

PMID:
17046183
22.

Downstream target genes of the neuropeptide S-NPSR1 pathway.

Vendelin J, Bruce S, Holopainen P, Pulkkinen V, Rytilä P, Pirskanen A, Rehn M, Laitinen T, Laitinen LA, Haahtela T, Saarialho-Kere U, Laitinen A, Kere J.

Hum Mol Genet. 2006 Oct 1;15(19):2923-35. Epub 2006 Aug 22.

PMID:
16926187
23.

Evaluation of cocktail approach to standardise Caco-2 permeability experiments.

Koljonen M, Hakala KS, Ahtola-Sätilä T, Laitinen L, Kostiainen R, Kotiaho T, Kaukonen AM, Hirvonen J.

Eur J Pharm Biopharm. 2006 Nov;64(3):379-87. Epub 2006 Jun 30.

PMID:
16914297
24.

A 10 year asthma programme in Finland: major change for the better.

Haahtela T, Tuomisto LE, Pietinalho A, Klaukka T, Erhola M, Kaila M, Nieminen MM, Kontula E, Laitinen LA.

Thorax. 2006 Aug;61(8):663-70.

25.

Predictors of COPD symptoms: does the sex of the patient matter?

Watson L, Schouten JP, Löfdahl CG, Pride NB, Laitinen LA, Postma DS; European Respiratory Society Study on Chronic Obstructive Pulmonary Disease.

Eur Respir J. 2006 Aug;28(2):311-8. Epub 2006 May 17.

26.

Neuropeptide S and G protein-coupled receptor 154 modulate macrophage immune responses.

Pulkkinen V, Majuri ML, Wang G, Holopainen P, Obase Y, Vendelin J, Wolff H, Rytilä P, Laitinen LA, Haahtela T, Laitinen T, Alenius H, Kere J, Rehn M.

Hum Mol Genet. 2006 May 15;15(10):1667-79. Epub 2006 Apr 6.

PMID:
16600990
27.

Predictors of lung function and its decline in mild to moderate COPD in association with gender: results from the Euroscop study.

Watson L, Vonk JM, Löfdahl CG, Pride NB, Pauwels RA, Laitinen LA, Schouten JP, Postma DS; European Respiratory Society Study on Chronic Obstructive Pulmonary Disease.

Respir Med. 2006 Apr;100(4):746-53. Epub 2005 Sep 30.

28.

Mesoporous silicon microparticles for oral drug delivery: loading and release of five model drugs.

Salonen J, Laitinen L, Kaukonen AM, Tuura J, Björkqvist M, Heikkilä T, Vähä-Heikkilä K, Hirvonen J, Lehto VP.

J Control Release. 2005 Nov 28;108(2-3):362-74. Epub 2005 Sep 19.

PMID:
16169628
29.

Preclinical evaluation of rapeseed, raspberry, and pine bark phenolics for health related effects.

Vuorela S, Kreander K, Karonen M, Nieminen R, Hämäläinen M, Galkin A, Laitinen L, Salminen JP, Moilanen E, Pihlaja K, Vuorela H, Vuorela P, Heinonen M.

J Agric Food Chem. 2005 Jul 27;53(15):5922-31.

PMID:
16028975
30.

Characterization of GPRA, a novel G protein-coupled receptor related to asthma.

Vendelin J, Pulkkinen V, Rehn M, Pirskanen A, Räisänen-Sokolowski A, Laitinen A, Laitinen LA, Kere J, Laitinen T.

Am J Respir Cell Mol Biol. 2005 Sep;33(3):262-70. Epub 2005 Jun 9.

PMID:
15947423
31.

Leukotriene E(4)-induced persistent eosinophilia and airway obstruction are reversed by zafirlukast in patients with asthma.

Laitinen A, Lindqvist A, Halme M, Altraja A, Laitinen LA.

J Allergy Clin Immunol. 2005 Feb;115(2):259-65.

PMID:
15696079
32.

Association analysis of common variants of STAT6, GATA3, and STAT4 to asthma and high serum IgE phenotypes.

Pykäläinen M, Kinos R, Valkonen S, Rydman P, Kilpeläinen M, Laitinen LA, Karjalainen J, Nieminen M, Hurme M, Kere J, Laitinen T, Lahesmaa R.

J Allergy Clin Immunol. 2005 Jan;115(1):80-7.

PMID:
15637551
33.

Personal memories of the history of stereotactic neurosurgery.

Laitinen LV.

Neurosurgery. 2004 Dec;55(6):1420-8; discussion 1428-9. Review.

PMID:
15574224
34.

Effects of extracts of commonly consumed food supplements and food fractions on the permeability of drugs across Caco-2 cell monolayers.

Laitinen LA, Tammela PS, Galkin A, Vuorela HJ, Marvola ML, Vuorela PM.

Pharm Res. 2004 Oct;21(10):1904-16.

PMID:
15553239
35.

[Sustained reduction in bronchial hyperresponsiveness within three days of inhaled fluticasone propionate in mild asthma:time course after onset and cessation of treatment].

Sovijärvi AR, Haahtela T, Ekroos HJ, Lindqvist A, Saarinen A, Poussa T, Laitinen LA.

Duodecim. 2004;120(13):1591-3. Finnish. No abstract available.

PMID:
15326966
36.

Association study of 15 novel single-nucleotide polymorphisms of the T-bet locus among Finnish asthma families.

Ylikoski E, Kinos R, Sirkkanen N, Pykäläinen M, Savolainen J, Laitinen LA, Kere J, Laitinen T, Lahesmaa R.

Clin Exp Allergy. 2004 Jul;34(7):1049-55.

PMID:
15248849
37.

Permeability characteristics and membrane affinity of flavonoids and alkyl gallates in Caco-2 cells and in phospholipid vesicles.

Tammela P, Laitinen L, Galkin A, Wennberg T, Heczko R, Vuorela H, Slotte JP, Vuorela P.

Arch Biochem Biophys. 2004 May 15;425(2):193-9.

PMID:
15111127
38.

Characterization of a common susceptibility locus for asthma-related traits.

Laitinen T, Polvi A, Rydman P, Vendelin J, Pulkkinen V, Salmikangas P, Mäkelä S, Rehn M, Pirskanen A, Rautanen A, Zucchelli M, Gullstén H, Leino M, Alenius H, Petäys T, Haahtela T, Laitinen A, Laprise C, Hudson TJ, Laitinen LA, Kere J.

Science. 2004 Apr 9;304(5668):300-4.

39.

Development of LC/MS/MS methods for cocktail dosed Caco-2 samples using atmospheric pressure photoionization and electrospray ionization.

Hakala KS, Laitinen L, Kaukonen AM, Hirvonen J, Kostiainen R, Kotiaho T.

Anal Chem. 2003 Nov 1;75(21):5969-77.

PMID:
14588039
40.

Airway inflammation and basement membrane tenascin in newly diagnosed atopic and nonatopic asthma.

Karjalainen EM, Lindqvist A, Laitinen LA, Kava T, Altraja A, Halme M, Laitinen A.

Respir Med. 2003 Sep;97(9):1045-51.

41.

Anterior capsulotomy for treatment of refractory obsessive-compulsive disorder: results in a young and an old patient.

Christensen DD, Laitinen LV, Schmidt LJ, Hariz MI.

Stereotact Funct Neurosurg. 2002;79(3-4):234-44.

PMID:
12890982
43.
44.

Sleep apnoea: Finnish National guidelines for prevention and treatment 2002-2012.

Laitinen LA, Anttalainen U, Pietinalho A, Hämäläinen P, Koskela K; Expert Advisory Group Listed in Foreword.

Respir Med. 2003 Apr;97(4):337-65.

45.

N-in-one permeability studies of heterogeneous sets of compounds across Caco-2 cell monolayers.

Laitinen L, Kangas H, Kaukonen AM, Hakala K, Kotiaho T, Kostiainen R, Hirvonen J.

Pharm Res. 2003 Feb;20(2):187-97.

PMID:
12636156
46.
47.

Respiratory symptoms and asthma in relation to cold climate, inhaled allergens, and irritants: a comparison between northern and southern Finland.

Kotaniemi JT, Pallasaho P, Sovijärvi AR, Laitinen LA, Lundbäck B.

J Asthma. 2002 Oct;39(7):649-58.

PMID:
12442955
48.

Short-term variability of exhaled nitric oxide in young male patients with mild asthma and in healthy subjects.

Ekroos H, Karjalainen J, Sarna S, Laitinen LA, Sovijärvi AR.

Respir Med. 2002 Nov;96(11):895-900.

49.

Prevalence and risk factors for asthma and chronic bronchitis in the capitals Helsinki, Stockholm, and Tallinn.

Pallasaho P, Lundbäck B, Meren M, Kiviloog J, Loit HM, Larsson K, Laitinen LA.

Respir Med. 2002 Oct;96(10):759-69.

50.

Psychosurgery.

Laitinen LV.

Stereotact Funct Neurosurg. 2001;76(3-4):239-42. Review.

PMID:
12378102

Supplemental Content

Loading ...
Support Center